Supercharge AML Translational Research

Best-in-class AML (acute myeloid leukemia) PDX models, a scalable 3D bone marrow niche ex vivo screening platform, and integrated biomarker services—built to de-risk AML therapeutic programs and accelerate go/no-go decisions. Request a consultation or quote to discuss custom study design.

Request a Quote

Download AML Factsheet

Why Partner With Crown Bioscience for AML Drug Development?

Crown Bioscience combines fully characterized AML PDX models, a physiologically relevant 3D bone marrow niche ex vivo screening platform, and end-to-end biomarker and bioanalysis services so translational teams can evaluate mechanism, efficacy, and resistance in clinically relevant systems.

Our AML Solutions

From ex vivo primary screening to in vivo PDX evaluation and biomarker readouts, choose modular or integrated study designs to fit your program needs.

Ex Vivo / In Vitro

Scalable 3D Bone Marrow Platform

This platform recreates the human bone marrow microenvironment for primary cell screening and mechanistic studies, ideal for evaluating niche-mediated resistance and targeted niche-directed strategies.

View Poster

In Vivo

Clinically Relevant AML PDX Models

Patient-derived AML models retain mutational and phenotypic features; these are designed for efficacy, combination testing, and residual disease studies with deep clinical/molecular annotation.

Read White Paper

AML Biomarker Analysis

Translational Biomarker Services

Leverage integrated OMICs, IHC, flow cytometry, and custom assay development to define PK/PD, patient stratification biomarkers, and resistance mechanisms.

Explore Biomarker Analysis

Models and Platforms

AML Models Built for Translational Fidelity

Our AML PDX cohort and model workflows prioritize retention of clinical features and treatment-history diversity to mirror patient heterogeneity. We support systemic AML models and engraftments in optimized immunodeficient strains for robust in vivo evaluation.

Explore PDX Models

Webinar

Advancing
Targeted Therapies

Understanding the complexity of the tumor microenvironment is critical for advancing therapies in hematologic cancers. In this 30-minute expert-led webinar, discover how Crown Bioscience’s innovative 3D in vitro bone marrow niche models and robust PDX models for AML and multiple myeloma are transforming preclinical research.

Watch On Demand Now

Bone Marrow Niche

A Physiologically Relevant Ex Vivo Screening Platform

Our 3D bone marrow niche replicates stromal and growth factor interactions to reveal niche-driven drug resistance and treatment escape, enabling more predictive primary screening and mechanistic interrogation than standard 2D assays. Download the factsheet or view our AACR poster for data and use cases.

View Factsheet

Biomarkers and Data

Translational Endpoints To Drive Decision-Making

We pair in vitro and in vivo models with OMICs, flow cytometry, and image-based high-content analysis to provide mechanistic insights and identify predictive biomarkers. Our data science team integrates datasets to support biomarker-led go/no-go decisions.

Read About Key Biomarkers for AML

Frequently Asked Questions

What types of AML models do you provide?

Primary patient-derived AML PDX models (systemic), characterized cell-based models, and ex vivo primary screening using our 3D bone marrow niche. We support various endpoints including survival, leukemic burden, flow cytometry, and molecular endpoints.

How is the bone marrow niche platform applied?

The platform enables scalable primary cell screening, evaluation of niche-mediated resistance, combination testing, and high-content imaging-based endpoint analyses. See the AACR 2025 poster for methods and representative data.

What biomarker assays are available for AML drug development?

NGS, targeted panels, proteomics, phosphoproteomics, IHC, flow cytometry, and custom assay development for PK/PD and translational biomarker identification.

How do you ensure model quality and relevance?

We perform molecular and clinical annotation and retain patient treatment-history metadata in select models to support translational matching. Our PDX models are engrafted into immunodeficient mouse strains, and we apply rigorous QC and annotation to maintain clinical relevance.

What are typical timelines and study design options for AML drug development?

Ex vivo screening takes weeks, short-term in vivo efficacy studies last for weeks to months, and longer PDX survival or resistance studies can take months. Contact our team to align timelines with your program milestones.

How do you handle biospecimens and patient data?

We use secure, characterized biospecimen workflows with appropriate consent and clinical metadata; data-sharing and licensing options are available.